Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Pawel Karol Mazur

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5820-8344; OpenAlex author ID A5089418989; NIH RePORTER profile ID 10802097. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 1)
Trials
0
Grants
4
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: none · 2014: none · 2015: 3 papers · 2016: 1 paper, 1 grant · 2017: 1 paper · 2018: none · 2019: 1 grant · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper, 2 grants · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 15

  1. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  2. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  3. Multifaceted role for p53 in pancreatic cancer suppression. Co-author DOI 10.1073/pnas.2211937120↗
  4. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  5. Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste". First author DOI 10.1158/1078-0432.ccr-18-0900↗
  6. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Last author DOI 10.1016/j.ccell.2020.04.014↗
  7. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Co-author DOI 10.1038/ncomms14294↗
  8. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. First author DOI 10.1101/gad.275529.115↗
  9. Current methods in mouse models of pancreatic cancer. Co-author DOI 10.1007/978-1-4939-2297-0_9↗
  10. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  11. Pancreatic cancer takes its Toll. Co-author DOI 10.1084/jem.21212insight1↗
  12. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. Co-author DOI 10.1002/path.3017↗
  13. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Co-author DOI 10.1136/gutjnl-2011-300756↗
  14. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0039424↗
  15. Early requirement of Rac1 in a mouse model of pancreatic cancer. Co-author DOI 10.1053/j.gastro.2011.04.043↗

Grants 4

  1. Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer R01CA236118↗
  2. Role of SETD5 in Chromatin Regulation and Tumorigenesis R01CA236949↗
  3. The SMYD3-ERK5 signaling module in pancreatic cancer R00CA197816↗
  4. The SMYD3-ERK5 signaling module in pancreatic cancer K99CA197816↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Or P. Gozani · 2 shared papers, 2 shared grants, 2016–2023 · strength 1.68
  2. Jens Thomas Siveke · 9 shared papers, 2011–2026 · strength 0.68
  3. Julien Sage · 7 shared papers, 2015–2026 · strength 0.66
  4. Stephano S. Mello · 4 shared papers, 2015–2026 · strength 0.54
  5. Laura D Attardi · 4 shared papers, 2015–2026 · strength 0.54
  6. Roland Michael Schmid · 6 shared papers, 2011–2026 · strength 0.52
  7. Elisabeth Heßmann · 4 shared papers, 2015–2026 · strength 0.46
  8. Volker Ellenrieder · 4 shared papers, 2015–2026 · strength 0.46
  9. Simone Hausmann · 4 shared papers, 2015–2026 · strength 0.46
  10. Alexander Herner · 4 shared papers, 2015–2026 · strength 0.45
  11. Iréne Esposito · 5 shared papers, 2012–2026 · strength 0.43
  12. Bence Sipos · 4 shared papers, 2011–2026 · strength 0.40
  13. Irina Heid · 4 shared papers, 2011–2026 · strength 0.40
  14. Marija Trajkovic‐Arsic · 4 shared papers, 2012–2026 · strength 0.40
  15. Jorg H. Kleeff · 4 shared papers, 2012–2026 · strength 0.40
  16. Mert Erkan · 3 shared papers, 2015–2026 · strength 0.37
  17. Stephan A. Hahn · 3 shared papers, 2015–2026 · strength 0.37
  18. Rickmer Braren · 3 shared papers, 2015–2026 · strength 0.37
  19. Matthias Wirth · 3 shared papers, 2015–2026 · strength 0.37
  20. Tyler Jacks · 3 shared papers, 2015–2026 · strength 0.37
  21. Robert Hester · 1 shared paper, 2021 · strength 0.22
  22. Florencia M. McAllister · 1 shared paper, 2021 · strength 0.22
  23. Sofia Ferreira · 1 shared paper, 2023 · strength 0.17
  24. Brittany M. Flowers · 1 shared paper, 2023 · strength 0.17
  25. James J. Lee · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.